Literature DB >> 28853729

Predictors of Early Readmission in Patients With Cirrhosis After the Resolution of Bacterial Infections.

Salvatore Piano1, Filippo Morando1, Giovanni Carretta2, Marta Tonon1, Elia Vettore1, Silvia Rosi1, Marialuisa Stanco1, Chiara Pilutti1, Antonietta Romano1, Alessandra Brocca1, Antonietta Sticca1, Daniele Donato2, Paolo Angeli1.   

Abstract

OBJECTIVES: In patients with cirrhosis, infections represent a frequent trigger for complications, increasing frequency of hospitalizations and mortality rate. This study aimed to identify predictors of early readmission (30 days) and of mid-term mortality (6 months) in patients with liver cirrhosis discharged after a hospitalization for bacterial and/or fungal infection.
METHODS: A total of 199 patients with cirrhosis discharged after an admission for a bacterial and/or fungal infection were included in the study and followed up for a least 6 months.
RESULTS: During follow-up, 69 patients (35%) were readmitted within 30 days from discharge. C-reactive protein (CRP) value at discharge (odds ratio (OR)=1.91; P=0.022), diagnosis of acute-on-chronic liver failure during the hospital stay (OR=2.48; P=0.008), and the hospitalization in the last 30 days previous to the admission/inclusion in the study (OR=1.50; P=0.042) were found to be independent predictors of readmission. During the 6-month follow-up, 47 patients (23%) died. Age (hazard ratio (HR)=1.05; P=0.001), model of end-stage liver disease (MELD) score (HR=1.13; P<0.001), CRP (HR=1.85; P=0.001), refractory ascites (HR=2.22; P=0.007), and diabetes (HR=2.41; P=0.010) were found to be independent predictors of 6-month mortality. Patients with a CRP >10 mg/l at discharge had a significantly higher probability of being readmitted within 30 days (44% vs. 24%; P=0.007) and a significantly lower probability of 6-month survival (62% vs. 88%; P<0.001) than those with a CRP ≤10 mg/l.
CONCLUSIONS: CRP showed to be a strong predictor of early hospital readmission and 6-month mortality in patients with cirrhosis after hospitalization for bacterial and/or fungal infection. CRP values could be used both in the stewardship of antibiotic treatment and to identify fragile patients who deserve a strict surveillance program.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28853729     DOI: 10.1038/ajg.2017.253

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  25 in total

1.  Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections.

Authors:  Maria Papp; Zsuzsanna Vitalis; Istvan Altorjay; Istvan Tornai; Miklos Udvardy; Jolan Harsfalvi; Andras Vida; Janos Kappelmayer; Peter L Lakatos; Peter Antal-Szalmas
Journal:  Liver Int       Date:  2011-12-06       Impact factor: 5.828

Review 2.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

3.  Diabetes as a risk factor for infections in cirrhosis.

Authors:  Javier Diaz; Eduardo Monge; Roxana Roman; Viviana Ulloa
Journal:  Am J Gastroenterol       Date:  2008-01       Impact factor: 10.864

4.  Rehospitalizations among patients in the Medicare fee-for-service program.

Authors:  Stephen F Jencks; Mark V Williams; Eric A Coleman
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

5.  Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.

Authors:  Paolo Angeli; Pere Ginès; Florence Wong; Mauro Bernardi; Thomas D Boyer; Alexander Gerbes; Richard Moreau; Rajiv Jalan; Shiv K Sarin; Salvatore Piano; Kevin Moore; Samuel S Lee; Francois Durand; Francesco Salerno; Paolo Caraceni; W Ray Kim; Vicente Arroyo; Guadalupe Garcia-Tsao
Journal:  J Hepatol       Date:  2015-01-28       Impact factor: 25.083

6.  Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study.

Authors:  Javier Fernández; Juan Acevedo; Miriam Castro; Orlando Garcia; Carlos Rodríguez de Lope; Daria Roca; Marco Pavesi; Elsa Sola; Leticia Moreira; Anibal Silva; Tiago Seva-Pereira; Francesco Corradi; Jose Mensa; Pere Ginès; Vicente Arroyo
Journal:  Hepatology       Date:  2012-04-04       Impact factor: 17.425

7.  The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis.

Authors:  Jasmohan S Bajaj; K Rajender Reddy; Puneeta Tandon; Florence Wong; Patrick S Kamath; Guadalupe Garcia-Tsao; Benedict Maliakkal; Scott W Biggins; Paul J Thuluvath; Michael B Fallon; Ram M Subramanian; Hugo Vargas; Leroy R Thacker; Jacqueline G O'Leary
Journal:  Hepatology       Date:  2016-02-19       Impact factor: 17.425

8.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

Authors:  Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo
Journal:  Gastroenterology       Date:  2013-03-06       Impact factor: 22.682

9.  An automated model using electronic medical record data identifies patients with cirrhosis at high risk for readmission.

Authors:  Amit G Singal; Robert S Rahimi; Christopher Clark; Ying Ma; Jennifer A Cuthbert; Don C Rockey; Ruben Amarasingham
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-13       Impact factor: 11.382

10.  Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure.

Authors:  Rajiv Jalan; Faouzi Saliba; Marco Pavesi; Alex Amoros; Richard Moreau; Pere Ginès; Eric Levesque; Francois Durand; Paolo Angeli; Paolo Caraceni; Corinna Hopf; Carlo Alessandria; Ezequiel Rodriguez; Pablo Solis-Muñoz; Wim Laleman; Jonel Trebicka; Stefan Zeuzem; Thierry Gustot; Rajeshwar Mookerjee; Laure Elkrief; German Soriano; Joan Cordoba; Filippo Morando; Alexander Gerbes; Banwari Agarwal; Didier Samuel; Mauro Bernardi; Vicente Arroyo
Journal:  J Hepatol       Date:  2014-06-17       Impact factor: 25.083

View more
  6 in total

1.  Hepatology in a changing health care landscape: A call for health services research.

Authors:  Lisa B VanWagner; Fasiha Kanwal
Journal:  Hepatology       Date:  2018-05-13       Impact factor: 17.425

2.  Hemoglobin A1c Has Suboptimal Performance to Diagnose and Monitor Diabetes Mellitus in Patients with Cirrhosis.

Authors:  Naga S Addepally; Nayana George; Roberto Martinez-Macias; Mauricio Garcia-Saenz-de-Sicilia; W Ray Kim; Andres Duarte-Rojo
Journal:  Dig Dis Sci       Date:  2018-08-29       Impact factor: 3.199

Review 3.  Acute on chronic liver failure in non-alcoholic fatty liver and alcohol associated liver disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  Transl Gastroenterol Hepatol       Date:  2019-10-11

4.  Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis.

Authors:  Jasmohan S Bajaj; Puneeta Tandon; Jacqueline G OʼLeary; Florence Wong; Scott W Biggins; Guadalupe Garcia-Tsao; Patrick S Kamath; Benedict Maliakkal; Michael B Fallon; Jennifer C Lai; Paul J Thuluvath; Hugo E Vargas; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Am J Gastroenterol       Date:  2019-04       Impact factor: 10.864

5.  Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever.

Authors:  Marta Tonon; Salvatore Piano
Journal:  Clin Mol Hepatol       Date:  2020-12-03

Review 6.  The mechanistic and prognostic implications of heart rate variability analysis in patients with cirrhosis.

Authors:  Noor-Ul-Hoda Abid; Ali R Mani
Journal:  Physiol Rep       Date:  2022-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.